Codexis to Participate in Piper Sandler 36th Annual Healthcare Conference REDWOOD CITY, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the Company will attend the Piper Sandler 36th Annual Healthcare Conference, being held December 3-5, 2024, in New York, New York. Management will participate in a fireside chat on Tuesday, December 3, 2024, at 11:00 am ET. A live webcast of the event will be available in the Investor Relations section of the Company’s ...
A director at Paycom Software Inc sold 3,900 shares at 229.094USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cle...
Codexis Unveils Pioneering Enzymatic Synthesis Data to Enable the Future Manufacturing of RNAi Therapeutics —Becomes first company to showcase four routes of synthesis for approved siRNA therapeutic asset— —Joint poster with Bachem demonstrates superiority of Company’s double-stranded RNA ligases compared to wild-type enzymes— —Management to host conference call today at 4:30 pm EST to discuss data— REDWOOD CITY, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today ...
Codexis Announces Appointment of Raymond De Vré, PhD, to Board of Directors REDWOOD CITY, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the appointment of Raymond De Vré, PhD, to the Company’s Board of Directors. “We are thrilled to have Raymond join the Codexis Board of Directors. He will be an invaluable resource to Codexis,” said Stephen Dilly, MBBS, PhD, Chairman and Chief Executive Officer at Codexis. “Raymond brings a deep understanding of the c...
Codexis TIDES Europe Presentations to Feature Next Step in Evolution of Enzymatic Synthesis for RNAi Therapeutics —Spotlight Presentation to showcase four routes of synthesis of an approved siRNA therapeutic asset— —Joint poster presentation with Bachem to compare Codexis double-stranded RNA ligase to wild-type enzymes— —Management to host conference call on Thursday, November 14 to discuss data— REDWOOD CITY, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today ann...
Codexis Announces New Employment Inducement Grants REDWOOD CITY, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the approval of an equity grant to one new employee as approved by the Compensation Committee of Codexis’ Board of Directors. The newly hired employee received an equity award consisting of (i) options to purchase 50,000 shares of Codexis common stock and (ii) 15,000 restricted stock units (RSUs) as an inducement award under the company’s 2024...
Codexis to Participate in Upcoming Healthcare Conferences REDWOOD CITY, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced that management will participate in four upcoming investor conferences. The Stifel 2024 Healthcare Conference (New York, NY) Monday, November 18, 2024, at 2:25 pm ET, management will participate in a fireside chat The Jefferies London Healthcare Conference (London, UK) Tuesday, November 19, 2024, at 9:30 am GMT, management will par...
Codexis Reports Third Quarter 2024 Financial Results Quarter Highlights Include Key Additions to Management Team and Extension of Cash Runway into 2027 with $31M Raise via ATM Facility Company Reiterates Full-year Financial Guidance; On Track to Achieve Product Revenue Growth of at Least 10% vs. FY2023 Excluding Enzyme Sales Related to PAXLOVID™ REDWOOD CITY, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced financial results for the third quarter ended ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.